{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 340, "pageCount": 415, "prevPage": 339, "nextPage": 341, "slideType": "quote_slide", "function": "expose_contradiction", "density": "overcrowded", "nDataPoints": 3, "notes": "The slide presents a transcript of an expert consultation call to undermine the market potential of Vykat.", "elementsJson": [ "headline_text", "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/340", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-340", "components": [ { "bbox": null, "kind": "callout", "text": "it's pretty quiet overall... what I'm not hearing people say, when can I get my hands on Vykat? Because we all know diazoxide, and we all know the problems with it. It's not like we're clueless. I'll put it this way...this somewhat surprising and out of the blue approval that I don't think any of us were quite expecting.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2b2-e9bff966551b", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.86, "x": 0.07, "y": 0.34 }, "kind": "paragraph", "text": "Endocrinologist sees 8-12 PW patients personally and ~20 at his institution; significant percentage of PWS population in Chicago area", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4c01da6e-b05f-41a2-a893-64c483aaa58d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.07, "w": 0.86, "x": 0.07, "y": 0.57 }, "kind": "paragraph", "text": "Q: \"So, you're basically in the know of a substantial percentage of the patients in the Chicago area. It sounds like you're in touch with the practitioners.\"\nA: \"I would say yes, that's true.\" – Endocrinologist with academic and community hospital affiliations", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "54e8886e-3e4d-493b-8fcf-f8fca139be7f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.39 }, "kind": "paragraph", "text": "A: \"I have appointments at Northwestern and also see patients at a local federally qualified health center. We're paired with our colleagues at [redacted], from whom we inherit quite a lot of these patients as they graduate to adult endocrinology clinics. I see somewhere between probably eight and 12 patients with Prader-Willi in a year.\"", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "571888a8-110c-4555-aecb-66baf6b2e8c2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.48 }, "kind": "paragraph", "text": "Q: \"How many Prader-Willi patients does Northwestern have? The institutions that you're affiliated with, roughly.\"\nA: \"I would say somewhere in the range of 20 or so...obviously, some of my colleagues have some of these patients, too. I would imagine that captures probably 50% of the Prader-Willi patients in their...\"", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "76a830fb-a372-4958-b879-d1e8e49aae59", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.66 }, "kind": "paragraph", "text": "No enthusiasm among practitioners for Vykat\nQ: \"What are you hearing as far as enthusiasm out there? Like at Northwestern, other institutions? Is there chatter? Are people emailing about this?\"\nA: \"I think what I'm hearing is — I would say it's pretty quiet overall. But there is, as you know, there is a desperation in the air about what to do about these patients. If, in fact, there are indications that generic diazoxide can work to reduce some of the hyperphagia and is worth a try before patients become diabetic, or to evaluate if they become seriously hyperglycemic, etc., then I think there will be enthusiasm for that approach. But essentially what I'm not hearing people say, when can I get my hands on Vykat? Because we all know diazoxide, and we all know the problems with it. It's not like we're clueless. I'm kind of waiting for some collegial conversations because we're really new into this somewhat surprising and out of the blue approval that I don't think any of us were quite expecting.\" - Endocrinologist; academic and community hospital affiliations.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d68df187-1f40-40f4-9920-46c6a29a05c2", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“it's pretty quiet overall... what I'm not hearing people say, when can I get my hands on Vykat? Because we all know diazoxide, and we all know the problems with it. It's not like we're clueless. I'll put it this way...this somewhat surprising and out of the blue approval that I don't think any of us were quite expecting.” — Endocrinologist; academic and community hospital affiliations", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2b2-ee8383f67927", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b786bfec-dc6c-4467-b794-608bc134d625", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "PWS endocrinologist #1: Affiliated with Northwestern University and a community hospital which collectively manage 50% of PWS patients in the Chicago area and in touch with those who manage the rest; approximately 20 patients and personally sees 8 to 12 annually. Surprised Vykat received FDA approval and indicated no enthusiasm for Vykat among physicians or patients – \"it's pretty quiet overall... what I'm not hearing people say, when can I get my hands on Vykat? Because we all know diazoxide, and we all know the problems with it. It's not like we're clueless. I'll put it this way...this somewhat surprising and out of the blue approval that I don't think any of us were quite expecting.\"", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "075fbc2a-df90-42f1-b1c4-ad95d0861549", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }